entirety, my feeling is that these data suggest that inhibitory heterotrimeric GTP-binding proteins connected to adenylyl cyclase convey the inhibitory signals of a-adrenergic agonists, but not those of IL-lfi, in the beta cell.
I am particularly concerned with the enormous concentrations of PTX and cholera toxin needed by Rabuazzo et al. [1] , to reverse the impact of IL-lfi. It should be noted that in their original studies with PTX, Katada and Ui [13] demonstrated reversibility of inhibition of insulin secretion with as little as 1 pg/ml of PTX; half-maximal recovery was recorded at 100 pg/ml, and levelling-off at 10 ng/ml of PTX. By contrast, Rabuazzo et al. [1] needed PTX concentrations as high as 0.5-2 ~tg/ml to detect a partial protective effect, whereas lower concentrations did not cause any significant effects [1] . Thus, one may want to entertain the idea that such heroic concentrations of toxin, amounting to = 106-times those needed by others [13] to significantly reverse inhibition of insulin secretion, may cause toxicity or other effects totally unrelated to influences on GTP-binding proteins. Additionally, it is evident from Table 1 that, at these concentrations, both cholera toxin and PTX had stimulatory effects of their own on insulin secretion [1] . Furthermore, it is well-known that PTX needs several hours to express its effects on the GTP-binding proteins [13] . This is the reason why islets were pretreated with the toxin in the papers by Sj6holm [7, 8, 10] and Eizirik et al. [9] . In order to arrive at the conclusion that IL-1/3 indeed exerts its action partially through interference with PTX-sensitive GTP-binding proteins, Rabuazzo et al. [1] may want to strengthen their case by demonstrating: 1) a GTP requirement for IL-lfl effects in beta-cell membrane preparations, 2) stimulation of a betacell GTPase by 1L-lfl, 3)the presence of an IL-lfi-specific PTX substrate, 4) that GTP-v-[S] inhibits the rate of PTX-catalysed ADP-ribosylation of such a particular substrate and 5) that, conversely, GDP-fi-[S] would stimulate such an activity.
Other questions that one would like to have seen addressed include how rates of hormone secretion recorded were related to possible effects of IL-lfi and the toxins on islet insulin and DNA contents. One possibility is that these huge concentrations of toxins may functionally impair the IL-lfl molecule, and it would be interesting to know how the authors have excluded this possibility. Additionally, the choice of statistical analysis appears inappropriate: in the multiple comparisons made in the study by Rabuazzo et al. [1] analysis of variance should be performed. What are the changes in islet cAMP con-tent after culture in the toxins, and why it is that forskolin cannot reverse the IL-1/3 effects when cholera toxin purportedly can? Finally, I find it hard to follow the argument [1] that differences in glucose metabolism known to exist between normal and tumoural beta-cells [8, 14] would account for the different responses to PTX. By contrast, it is IL-1/3 and not PTX (Table 2 [1] ) that affects glucose oxidation rates, whereas the inhibitory effects of IL-1/3 remain qualitatively similar between normal [7, 9 , 10] and tumoural [8, 15] beta cells.
Thus, the line of objections outlined above makes me feel that it remains ambiguous, at best, whether IL-1/3 indeed acts specifically through PTX-sensitive GTP-binding proteins in suppressing beta-cell function. However, this by no means contradicts the possibility that the cytokine interferes with GTPbinding proteins not sensitive to PTX, as has been shown in other tissues [16] .
Yours sincerely, A. Sj6holm Response from the authors Dear Sir, Dr. Sj6holm disagrees with our recent report [1] that G-proteins may be involved in the inhibition of insulin release by interleukin-1/3 (IL-1/3). He raises several points that I would like to address. The main criticism relates to the dose of pertussis toxin (PTX) that we have used, 'scientifically' defined as 'heroic' by Dr. Sj6holm. We found a detectable effect at 0.2 ~g/ ml, and a plateau at 0. (which opens K + channels), Gpl c (which activates phospholipase C), Gpl a (which activates phospholipase A), G 1 (transducin) and G o (function uncertain) [6] . The PTX dose that interacts with G i in pancreatic islets may be different from the PTX dose that interacts with G k or Gpl c. In addition, the PTX sensitivity of the different G-proteins may change in the different experimental models (RIN, HIT, fetal or adult rat islets). Dr. Sj6holm reports [7, 8] that PTX (at a single concentration) blocked inhibition of insulin release evoked by alpha-adrenoreceptor agonists and not by IL-lfi; in my opinion this simply suggests that alpha-adrenoreceptor agonists and IL-1/3 may interact with different G-proteins. To summarise, therefore, I totally disagree with the comment that we have used 'concentrations of toxin amounting to -106 times those needed by others', and I find it more interesting to understand the scientific reasons to explain the different PTX concentrations used, to gain further information on the IL-1/3 mechanism of action.
Other criticisms relate to the choice of statistical analysis (using the analysis of variance, the results of Table 1 and 2 would be similar), and to some speculation in the Discussion (differences in glucose metabolism known to exist between normal and tumoural cells seem to be due to different isoenzyme expression or activity. PTX-sensitive G-proteins may differently influence these enzymes).
In our report, from the Title to the Discussion we emphasise that we are only in a preliminary phase, and that the precise G-protein(s) involved as effector in this system is unknown. A series of more direct studies is now possible using our experimental model, to better clarify the role of G-proteins in mediating IL-lfl effects on pancreatic islets.
Yours sincerely, E Purrello

Large-scale study of an A-to-G transition at position 3243 of the mitochondrial gene and IDDM in Japanese patients
Dear Sir,
The most frequent gene mutation in Japanese patients with non-insulin-dependent diabetes mellitus (NIDDM) was recently reported to be an A-to-G transition at position 3243 of the mitochondrial gene (3243 base pair (bp) mutation) (-1%). Otabe et al. [1] and Odawara et al. [2] identified it in 5 of 550 NIDDM patients and 3 of 300 NIDDM patients who also had impaired glucose tolerance (IGT). It seems that approximately 1% of the cases of NIDDM in Japanese patients may be strongly associated with and/or caused by the 3243 bp mitochondrial gene mutation. On the other hand, Oka et al. [3] reported that approximately 10 % of patients with slowly progressive insulin-dependent diabetes (IDDM), which was characterized by a clinical course including a period of several years without insulin treatment, decreasing C-peptide response and tong-term islet cell antibody positivity, had the 3243 bp mitochondrial mutation. Indeed, it is sometimes difficult to determine the type of diabetes in lean young Japanese patients because they sometimes exhibit a low C-peptide response which requires insulin treatment without abrupt onset of diabetes, and proneness to ketosis. We recently reported that 6 of 102 (5.9 %) lean female patients who developed NIDDM at a young age (25.0_+ 6.3 years) had the 3243 bp mitochondrial mutation; these six patients were diagnosed as having insulin-requiring NIDDM because they did not exhibit abrupt onset of diabetes or ketoCorresponding author." Dr. Y. Uchigata, Diabetes Center, Tokyo Women's Medical College, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162, Japan sis/ketoacidosis. Moreover, we reported that none of 64 IDDM patients had the 3243 bp mutation [4] . Although Odawara et al. [2] reported a similar finding (among 94 IDDM patients no patients with the 3243 bp mutation were found), it is difficult to support statistically the lack of an association between the 3243 bp mutation and IDDM development based only on such small-scale studies of IDDM patients. Therefore, we conducted a large-scale study to investigate whether patients with well-defined IDDM possess the 3243 bp mutation which might produce autoimmunity leading to IDDM.
The study population (n = 568, male/female = 203/365 [5] ) comprised 489 IDDM patients who were residents of the Tokyo area treated at the Diabetes Center, Tokyo Women's Medical College, 29 IDDM patients treated at several hospitals who were residents of the "Hokkaido" area and 50 IDDM patients treated at the Department of Geriatric Medicine, Osaka University Medical School who were residents of the Osaka area. The diagnosis of IDDM was based on the criteria of the National Diabetes Data Group with a further requirement of low C-peptide values. The 3243 bp mutation in mitochondrial DNA extracted fi'om peripheral blood cells was detected using the polymerase chain reaction (PCR) method with a probe specific to this mutation [6] ; the PCR products were digested with the restriction endonuclease Apa I followed by silver staining [4] . Using this method we detected 0.6 % heteroplasmy of the mutation [4] . Table I shows the baseline characteristics of the IDDM patients divided into four groups. Some of them had parents with NIDDM or siblings with IDDM. The frequency of coma or ketoacidosis at the time of diagnosis showed significant differences in age at onset (p < 0.002). The greater the age at onset, the less frequent was coma or ketoacidosis at the time of diagnosis. The 3243 bp mutation was not detected in any of the IDDM patients (p = 0.0285 vs 5 of 550 NIDDM patients [1] and p = 0.0418 vs 3 of 300 NIDDM + IGT patients [2] by Fisher's exact probability analysis). The result of this study demon-
